Evidence map›Paper›PMID 38808863›Full record

ArticleJournal of primary care & community health

Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs.

Ravindra Ganesh, Siddhant Yadav, Ryan T Hurt, Michael R Mueller, Christopher A Aakre, Elizabeth A Gilman, Stephanie L Grach, Joshua Overgaard, Melissa R Snyder, Nerissa M Collins and 4 more

Abstract read
In one paragraph

Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Review
  3. CD169Frontiers in cellular and infection microbiology · 2026
    Article
  4. Review
  5. COVID-19 and Lung Cancer Interactions: A Literature Review.Medical sciences (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ravindra GaneshMayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6877-1712
Siddhant YadavMayo Clinic, Rochester, MN, USA.
Ryan T HurtMayo Clinic, Rochester, MN, USA.
Michael R MuellerMayo Clinic, Rochester, MN, USA.
Christopher A AakreMayo Clinic, Rochester, MN, USA.
Elizabeth A GilmanMayo Clinic, Rochester, MN, USA.
Stephanie L GrachMayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8337-6219
Joshua OvergaardMayo Clinic, Rochester, MN, USA.
Melissa R SnyderMayo Clinic, Rochester, MN, USA.
Nerissa M CollinsMayo Clinic, Rochester, MN, USA.
Ivana T CroghanMayo Clinic, Rochester, MN, USA.ORCID 0000-0003-3464-3525
Andrew D BadleyMayo Clinic, Rochester, MN, USA.
Raymund R RazonableMayo Clinic, Rochester, MN, USA.
Bradley R SalonenMayo Clinic, Rochester, MN, USA.

Funding

Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI110173NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698
6 · The paper itself

Abstract

backgroundOver 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs.

methodsThe clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants.

resultsA total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α ( DISCUSSION: When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.

Indexed as

COVID-19CytokinesSARS-CoV-2AdultFemaleHumansInterleukin-1betaInterleukin-6MaleMiddle AgedPost-Acute COVID-19 SyndromeTumor Necrosis Factor-alphaCytokinesInterleukin-1betaInterleukin-6Tumor Necrosis Factor-alphacytokineslong COVIDPASCSARS-CoV-2variants

Identifiers

PMID38808863
PMCPMC11138192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.